New therapy aims to lift depression in HIV-Positive teens

NCT ID NCT07211087

Not yet recruiting Symptom relief Sponsor: Rhode Island Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an enhanced version of depression treatment (COMBEX) for youth aged 15-24 with HIV. It combines therapy, medication management, and extra support strategies to improve mood and HIV care. Researchers will compare it to standard combination therapy over 72 weeks in 130 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: behavioral therapy (cognitive behavioral therapy and medication management)
What this could lead to: If successful, this could provide a more effective, sustainable way to treat depression in youth with HIV, improving both mental health and HIV outcomes.
What could go wrong: This is an early-stage behavioral trial with 130 participants, so results may not apply broadly. The enhanced therapy may not significantly outperform the standard approach.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS depressive disorder dysthymic disorder HIV infectious disease major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSION DISORDERS HIV (HUMAN IMMUNODEFICIENCY VIRUS)

More trials for these conditions

Other studies related to the condition(s) this trial covers.